Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Spotlight picks
- Trial result Spotlight
Multiple myeloma
Teclistamab (BCMAxCD3 bispecific) drives 78% CR and 92% 2-year PFS in high-risk smoldering myeloma
Teclistamab is a BCMA-targeting T-cell–redirecting bispecific antibody tested as a fixed-duration “immune interception” strategy in the randomized Phase 2 ImmunoPRISM trial (NCT05469893) versus…
NCT05469893 - New trial Spotlight
Pancreatic cancer
Phase 3 zoldonrasib (RMC-9805) KRAS G12D RAS(ON) inhibitor + daraxonrasib (RMC-6236) RAS(ON) multi-selective inhibitor
Revolution Medicines’ RASolute 309 is a Phase 3, randomized, open-label study testing whether dual RAS(ON) blockade improves outcomes versus standard chemotherapy in first-line metastatic pancreatic adenocarcinoma…
NCT07805954 Registrational - New trial Spotlight
Brain and CNS tumors
Phase 2 safusidenib erbumine mutant-IDH1 inhibitor in post-vorasidenib progressive IDH1 glioma.
Nuvation Bio’s multicenter Phase 2 study tests safusidenib erbumine (250 mg orally twice daily), a brain-penetrant small-molecule inhibitor of mutant IDH1 (including IDH1 R132) that lowers the oncometabolite…
NCT07703436 Exploratory - Trial result Spotlight
Non-small cell lung cancer
Daraxonrasib (RMC-6236) RAS(ON) tri-complex inhibitor delivers 37% ORR in previously treated RAS-mutant NSCLC
Daraxonrasib (RMC-6236) is an oral, multiselective RAS(ON) tri-complex inhibitor that binds active, GTP-bound mutant and wild-type RAS isoforms; it was evaluated in the Phase 1–2 RMC-6236-001 study (NCT05379985) in…
NCT05379985 - Trial result Spotlight
Uterine (endometrial) cancer
Ribociclib (CDK4/6) + everolimus (mTOR) + letrozole (aromatase) lifts ORR only in endocrine-pretreated recurrent endometrial cancer
Everolimus (oral mTORC1 inhibitor) plus letrozole (aromatase inhibitor) was tested with vs without ribociclib (CDK4/6 inhibitor) in a randomized Phase 2 recurrent endometrial cancer trial (NCT03008408). In the…
NCT03008408 - Trial result Spotlight
Head and neck cancer
Pemetrexed (antifolate chemo) + pembrolizumab (PD-1) delivers 37.5% ORR—and 63.6% in salivary duct carcinoma—in R/M salivary gland cancer
MC200708 (NCT04895735) is a single-arm Phase II (Simon two-stage) testing pemetrexed 500mg/m² IV q3w + pembrolizumab 200mg IV q3w in recurrent/metastatic non-adenoid cystic salivary gland cancers; any number of prior…
NCT04895735 - Trial result Spotlight
Pancreatic cancer
L-Glutamine + Gem/Nab-P Reaches 22-Month mOS in Advanced PDAC
The Phase 1 GlutaPanc trial (NCT04634539) added oral L-glutamine—a metabolic intervention with preclinical evidence of sensitizing pancreatic cancer to chemotherapy—to first-line gemcitabine + nab-paclitaxel in…
NCT04634539 - New trial Spotlight
Lymphoma
Phase 2 teclistamab BCMA×CD3 T‑cell–redirecting bispecific antibody in R/R Waldenström’s macroglobulinemia.
This single-group, open-label Phase 2 study evaluates teclistamab (a BCMA×CD3 bispecific monoclonal antibody that redirects T cells to kill BCMA-expressing malignant B-lineage cells) in relapsed or refractory…
NCT07791498 Exploratory - New trial Spotlight
Prostate cancer
Phase 1/2 ADI-212 PSMA-targeted γδ (Vδ1) CAR-T cells in mCRPC.
This Phase 1/2 multicenter, open-label, dose-escalation (3+3) and dose-expansion study evaluates ADI-212, an allogeneic engineered γδ (Vδ1) CAR-T cell therapy that targets PSMA on prostate cancer cells, sponsored by…
NCT07793435 First-in-human - New trial Spotlight
Colorectal cancer
Phase 3 petosemtamab (EGFR×LGR5 bispecific antibody) vs cetuximab in 1L left-sided mCRC
Genmab’s LiGeR-CRC1 is a randomized, open-label Phase 3 trial testing whether petosemtamab (MCLA-158; an EGFR×LGR5-directed bispecific monoclonal antibody designed to block EGFR signaling and target LGR5-expressing…
NCT07702032 Registrational - New trial Spotlight
Multiple solid tumors
Phase 2 SIR2501 SARM1 inhibitor aims to prevent paclitaxel-induced peripheral neuropathy.
This Phase 2, open-label, sequential-cohort study evaluates SIR2501 in adults with solid tumors who are scheduled to receive paclitaxel-based chemotherapy, with primary goals of characterizing safety, tolerability,…
NCT07765446 Exploratory - Trial result Spotlight
Non-small cell lung cancer
Sutetinib (irreversible EGFR-TKI) drives 70.8% ORR and 13.7-mo PFS in 1L uncommon EGFR-mutant NSCLC
Sutetinib is an oral irreversible EGFR tyrosine kinase inhibitor (TKI) evaluated in a multicenter, open-label, single-arm Phase IIb trial in locally advanced/metastatic NSCLC with uncommon EGFR mutations (G719X,…
NCT05168566 - Trial result Spotlight
Lymphoma
BV (CD30-directed ADC) + nivolumab (PD-1) + limited chemo delivers 97% 2-year PFS in nonbulky early-stage cHL (SGN35-027)
Brentuximab vedotin (BV) is a CD30-targeted antibody–drug conjugate and nivolumab is a PD-1 checkpoint inhibitor; in SGN35-027 Part C (Phase 2; NCT03646123), previously untreated Ann Arbor stage I–II nonbulky…
NCT03646123 - New trial Spotlight
Non-small cell lung cancer
Phase 3 zoldonrasib (RMC-9805) KRAS G12D-selective RAS(ON) inhibitor + pembrolizumab chemo in NSCLC
Revolution Medicines is running RASolve 308, a randomized, double-blind, placebo-controlled Phase 3 trial testing whether adding zoldonrasib (RMC-9805)—a KRAS G12D-selective, active-state “RAS(ON)” small-molecule…
NCT07777822 Registrational - New trial Spotlight
Non-small cell lung cancer
Phase 3 divarasib KRAS G12C inhibitor vs PD-1 immunotherapy/observation after resection.
Hoffmann‑La Roche’s KRASCENDO 3 (Phase 3, randomized, open-label) tests whether divarasib—an oral, covalent KRAS G12C small‑molecule inhibitor—improves outcomes versus investigator’s choice of pembrolizumab (Merck)…
NCT07541170 Registrational - New trial Spotlight
Head and neck cancer
Phase 3 CRB-701 nectin-4–targeted ADC (MMAE tubulin inhibitor) vs chemo/EGFR options in R/M OPSCC
Corbus Pharmaceuticals’ TEMPO-1 is a randomized, open-label, 2-arm Phase 3 trial testing CRB-701 (also referenced as SYS6002), a nectin-4–directed monoclonal antibody–drug conjugate that delivers the microtubule…
NCT07768189 Registrational - New trial Spotlight
Colorectal cancer
Phase 2 ivonescimab PD-1×VEGF bispecific antibody plus intraperitoneal paclitaxel chemotherapy
MD Anderson Cancer Center is running this Phase 2, single-arm study testing ivonescimab (a PD-1 and VEGF-targeted bispecific antibody; developed by Akeso Biopharma and partnered by Summit Therapeutics) combined with…
NCT07753824 Exploratory - New trial Spotlight
Acute myeloid leukemia and MDS
Phase 2/3 Pivekimab sunirine CD123-targeted ADC (IGN payload) + venetoclax/azacitidine in AML
AbbVie’s randomized Phase 2/3 trial (NCT07581002) tests whether adding pivekimab sunirine (PVEK)—a CD123-directed monoclonal antibody–drug conjugate carrying an indolinobenzodiazepine (IGN) DNA-alkylating payload—can…
NCT07581002 Registrational - New trial Spotlight
Liver and bile duct cancer
Phase 2a pemigatinib FGFR1/2/3 inhibitor alternated with durvalumab PD‑L1 blockade
This Ohio State University Comprehensive Cancer Center Phase 2a study tests a “cyclical/alternating” first-line strategy for unresectable, locally advanced, or metastatic biliary tract cancers (commonly intrahepatic…
NCT07780838 Exploratory - Trial result Spotlight
Lymphoma
Epcoritamab (CD3×CD20 bispecific) + R-CHOP Drives 85% CR and 80% 2-year PFS in High-Risk Newly Diagnosed LBCL
Epcoritamab is a subcutaneous CD3×CD20 bispecific T-cell–engaging antibody added to standard R-CHOP, aiming to deepen frontline remissions in CD20+ large B-cell lymphoma (LBCL). In Arm 1 of the Phase 1b/2 EPCORE…
NCT04663347 - Trial result Spotlight
Head and neck cancer
TG4050 (individualized MVA neoantigen vaccine) shows 0/16 per-protocol relapses at 30 months in resected HPV-negative HNSCC
TG4050 is a personalized therapeutic cancer vaccine delivered through a Modified Vaccinia Ankara (MVA) vector encoding up to 30 patient-specific predicted neoantigens to generate tumor-directed T-cell immunity. In…
NCT04183166 - Trial result Spotlight
Colorectal cancer
Sotorasib (KRAS G12C inhibitor) + panitumumab (EGFR mAb) + FOLFIRI drives 56.5% ORR in pretreated KRAS G12C mCRC
Sotorasib is an oral covalent KRAS G12C inhibitor and panitumumab is an EGFR-targeting monoclonal antibody; here they were combined with irinotecan/leucovorin/5-FU (FOLFIRI) in the CodeBreaK 101 Phase 1b subprotocol…
NCT04185883 - New trial Spotlight
Pancreatic cancer
Phase 1b/2 ANO31905 CLDN18.2×CD3 bispecific + chemo in first-line PDAC
This open-label, nonrandomized Phase 1b/2 study (n=84) tests two dose levels of ANO31905 plus gemcitabine and nab-paclitaxel in untreated CLDN18.2-positive locally advanced unresectable or metastatic pancreatic…
NCT07444541 Exploratory - New trial Spotlight
Prostate cancer
Phase 2 MRT-2359 GSPT1 molecular glue degrader + apalutamide AR inhibitor in AR-mutant mCRPC.
This Phase 2 open-label, multicenter study (MODeFIRe-1) from Monte Rosa Therapeutics tests oral MRT-2359 plus apalutamide in patients with castration-resistant prostate adenocarcinoma whose tumors harbor androgen…
NCT07745361 Exploratory - New trial Spotlight
Breast cancer
Phase 2 pembrolizumab PD‑1 inhibitor with anthracycline-sparing neoadjuvant chemo in high‑TIL TNBC
This Phase 2 NeoTILs study from the Medical University of South Carolina (MUSC) tests a biomarker-guided de-escalation strategy in stage II–IIIB triple-negative or hormone receptor–low (ER/PR <10%) invasive breast…
NCT07743190 Exploratory - New trial Spotlight
Small cell lung cancer
Phase 3 ABBV-706 SEZ6-targeted topo-1 ADC vs chemotherapy in R/R SCLC
AbbVie’s randomized, open-label Phase 3 trial tests ABBV-706 against physician’s-choice topotecan, lurbinectedin, or amrubicin in roughly 531 patients with relapsed/refractory SCLC. ABBV-706 is a SEZ6-directed…
NCT07365241 Registrational - New trial Spotlight
Ovarian cancer
Phase 1 ARR-002 dual-target MUC16/NaPi2b ADC (vcMMAE microtubule inhibitor payload) in ovarian/endometrial cancer.
This first-in-human, open-label, multicenter Phase 1a/1b dose-escalation/expansion study evaluates ARR-002 in adults with locally advanced or metastatic ovarian or endometrial cancer. ARR-002 (ArriVent BioPharma) is…
NCT07755436 First-in-human - New trial Spotlight
Kidney cancer
Phase 3 belzutifan HIF-2α inhibitor + zanzalintinib multi-kinase VEGFR/c-MET inhibitor in advanced RCC.
Merck Sharp & Dohme (MSD) is running LITESPARK-034 (MK-6482-034), a Phase 3 randomized, double-blind study testing belzutifan plus zanzalintinib versus belzutifan plus placebo in advanced/unresectable renal cell…
NCT07489495 Registrational - Trial result Spotlight
Melanoma
Spartalizumab (PD-1) + Dabrafenib/Trametinib Extends OS vs BRAF/MEK Alone in BRAF V600 Melanoma
Spartalizumab is an anti–PD-1 monoclonal antibody combined here with dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) as first-line targeted therapy intensification for BRAF V600-mutant…
NCT02967692 - Trial result Spotlight
Prostate cancer
Olaparib (PARP inhibitor) + Abiraterone Shows BRCA2-Driven Benefit in 1L mCRPC
Olaparib is an oral PARP inhibitor combined here with abiraterone, a CYP17 androgen-biosynthesis inhibitor, plus prednisone/prednisolone in the randomized, double-blind Phase 3 PROpel trial (NCT03732820) in…
NCT03732820
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.